Belimumab for the treatment of systemic lupus erythematosus. (February 2014)

• Record Type: Journal Article
• Authors: Jordan, Natasha; D'Cruz, David P
• Is Part Of: Expert review of clinical immunology. Volume 11:Number 2(2015)
• Page Start: 195
• Page End: 204
• Publication Date: 2014-02
• Subjects: Clinical immunology -- Periodicals; 616.079
• DOI: 10.1586/1744666X.2015.996550
• Languages: English
• ISSNs: 1744-666X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Given their pivotal role in autoantibody production, B-cells have become an attractive therapeutic target in systemic lupus erythematosus (SLE). Belimumab, a fully human monoclonal antibody against B lymphocyte stimulator (BLyS), a B-cell survival factor, was licensed in 2011 for the treatment of autoantibody-positive SLE. The BLISS-52 and BLISS-76 Phase III trials successfully demonstrated that belimumab (10 mg/kg) with standard therapy significantly decreased disease activity in SLE patients compared to placebo with standard therapy. Overall, belimumab has been found to be safe and well tolerated. While the BLISS-52 and BLISS-76 studies are the largest clinical trials in SLE to date, they mainly focused on musculoskeletal, mucocutaneous, hematologic and general constitutional features of the disease. Patients with severe lupus nephritis and severe central nervous system disease were excluded from these trials. Studies of belimumab in lupus nephritis are ongoing that may clarify the role of this agent in the clinical management of SLE.</p> </abstract>